Concepts (248)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 12 | 2024 | 64 | 1.910 |
Why?
|
| Hepatitis B, Chronic | 5 | 2023 | 27 | 1.430 |
Why?
|
| Hepatitis C | 7 | 2023 | 65 | 1.250 |
Why?
|
| Antiviral Agents | 12 | 2024 | 94 | 1.200 |
Why?
|
| Liver Cirrhosis | 6 | 2024 | 35 | 0.810 |
Why?
|
| Sustained Virologic Response | 6 | 2023 | 17 | 0.740 |
Why?
|
| Humans | 53 | 2024 | 17611 | 0.710 |
Why?
|
| Female | 42 | 2024 | 12608 | 0.660 |
Why?
|
| Quality of Life | 4 | 2023 | 507 | 0.650 |
Why?
|
| Stress, Psychological | 1 | 2020 | 141 | 0.620 |
Why?
|
| Health Status | 1 | 2020 | 298 | 0.590 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2023 | 26 | 0.590 |
Why?
|
| Hawaii | 12 | 2023 | 42 | 0.580 |
Why?
|
| Suicide | 3 | 2024 | 123 | 0.570 |
Why?
|
| Liver Neoplasms | 3 | 2023 | 40 | 0.570 |
Why?
|
| Male | 27 | 2024 | 10008 | 0.510 |
Why?
|
| Hepacivirus | 9 | 2024 | 51 | 0.500 |
Why?
|
| Adult | 22 | 2024 | 7598 | 0.480 |
Why?
|
| Mental Disorders | 3 | 2022 | 280 | 0.470 |
Why?
|
| Patient Health Questionnaire | 2 | 2024 | 18 | 0.450 |
Why?
|
| Middle Aged | 23 | 2024 | 7911 | 0.450 |
Why?
|
| Cataract Extraction | 1 | 2012 | 3 | 0.410 |
Why?
|
| Cataract | 1 | 2012 | 10 | 0.400 |
Why?
|
| Rural Population | 1 | 2012 | 51 | 0.400 |
Why?
|
| Adolescent | 20 | 2024 | 3651 | 0.390 |
Why?
|
| United States | 13 | 2024 | 3956 | 0.390 |
Why?
|
| Prevalence | 5 | 2023 | 884 | 0.370 |
Why?
|
| Aged | 15 | 2024 | 6095 | 0.370 |
Why?
|
| Coinfection | 2 | 2023 | 30 | 0.360 |
Why?
|
| Hepatitis B | 2 | 2023 | 42 | 0.350 |
Why?
|
| Mental Health | 2 | 2023 | 165 | 0.350 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 2 | 2022 | 12 | 0.350 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 2 | 2007 | 4 | 0.340 |
Why?
|
| Risk Factors | 10 | 2022 | 3325 | 0.340 |
Why?
|
| Diet | 3 | 2007 | 365 | 0.330 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 255 | 0.330 |
Why?
|
| Retrospective Studies | 8 | 2024 | 2447 | 0.320 |
Why?
|
| Absorptiometry, Photon | 4 | 2011 | 50 | 0.300 |
Why?
|
| Cohort Studies | 12 | 2024 | 2570 | 0.290 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2019 | 748 | 0.280 |
Why?
|
| Self-Injurious Behavior | 2 | 2024 | 44 | 0.280 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2006 | 7 | 0.270 |
Why?
|
| Feeding Behavior | 2 | 2007 | 166 | 0.260 |
Why?
|
| Breast Neoplasms | 5 | 2017 | 949 | 0.260 |
Why?
|
| Hepatitis B virus | 3 | 2023 | 20 | 0.250 |
Why?
|
| Mastitis | 1 | 2024 | 2 | 0.250 |
Why?
|
| Clozapine | 1 | 2024 | 5 | 0.240 |
Why?
|
| International Classification of Diseases | 1 | 2024 | 85 | 0.230 |
Why?
|
| Aminoisobutyric Acids | 1 | 2024 | 2 | 0.230 |
Why?
|
| Cyclopropanes | 1 | 2024 | 2 | 0.230 |
Why?
|
| Lactams, Macrocyclic | 1 | 2024 | 2 | 0.230 |
Why?
|
| Leucine | 1 | 2024 | 3 | 0.230 |
Why?
|
| Benzimidazoles | 1 | 2024 | 6 | 0.230 |
Why?
|
| Proline | 1 | 2024 | 5 | 0.230 |
Why?
|
| Sulfonamides | 1 | 2024 | 14 | 0.230 |
Why?
|
| Body Mass Index | 4 | 2022 | 958 | 0.230 |
Why?
|
| Adipose Tissue | 5 | 2011 | 58 | 0.230 |
Why?
|
| Obesity | 3 | 2024 | 837 | 0.230 |
Why?
|
| Antipsychotic Agents | 1 | 2024 | 49 | 0.220 |
Why?
|
| Psychotic Disorders | 1 | 2024 | 44 | 0.220 |
Why?
|
| ras Proteins | 2 | 2014 | 20 | 0.220 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2014 | 32 | 0.220 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2023 | 10 | 0.210 |
Why?
|
| Latent Tuberculosis | 1 | 2023 | 10 | 0.210 |
Why?
|
| Opportunistic Infections | 1 | 2022 | 7 | 0.210 |
Why?
|
| Ribavirin | 2 | 2019 | 8 | 0.210 |
Why?
|
| African Americans | 3 | 2020 | 472 | 0.200 |
Why?
|
| Breast | 3 | 2011 | 84 | 0.200 |
Why?
|
| Carbonated Beverages | 3 | 2007 | 14 | 0.200 |
Why?
|
| Pregnancy Outcome | 1 | 2022 | 154 | 0.190 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 289 | 0.190 |
Why?
|
| Surveys and Questionnaires | 4 | 2022 | 1309 | 0.190 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 568 | 0.190 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 201 | 0.190 |
Why?
|
| Weight Gain | 1 | 2022 | 173 | 0.180 |
Why?
|
| Young Adult | 7 | 2024 | 2427 | 0.180 |
Why?
|
| Psychology | 1 | 2020 | 16 | 0.180 |
Why?
|
| Overweight | 1 | 2022 | 269 | 0.180 |
Why?
|
| Cholagogues and Choleretics | 1 | 2020 | 2 | 0.180 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2020 | 2 | 0.180 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2020 | 2 | 0.180 |
Why?
|
| Autism Spectrum Disorder | 1 | 2023 | 163 | 0.180 |
Why?
|
| Physician's Role | 1 | 2020 | 31 | 0.170 |
Why?
|
| Unemployment | 1 | 2020 | 11 | 0.170 |
Why?
|
| Psychiatry | 1 | 2020 | 23 | 0.170 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 19 | 0.170 |
Why?
|
| Electronic Health Records | 1 | 2024 | 681 | 0.170 |
Why?
|
| Incidence | 5 | 2022 | 1255 | 0.160 |
Why?
|
| Puberty | 2 | 2011 | 58 | 0.160 |
Why?
|
| Prospective Studies | 5 | 2023 | 1267 | 0.160 |
Why?
|
| China | 2 | 2024 | 130 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2024 | 1259 | 0.160 |
Why?
|
| Social Support | 1 | 2020 | 203 | 0.150 |
Why?
|
| Mental Health Services | 1 | 2020 | 154 | 0.150 |
Why?
|
| Virus Activation | 1 | 2018 | 6 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 48 | 0.150 |
Why?
|
| Time Factors | 5 | 2019 | 1086 | 0.150 |
Why?
|
| Comorbidity | 1 | 2020 | 594 | 0.150 |
Why?
|
| Neoplasms | 1 | 2022 | 438 | 0.150 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 598 | 0.150 |
Why?
|
| Child | 8 | 2023 | 2474 | 0.150 |
Why?
|
| Liver | 1 | 2017 | 32 | 0.140 |
Why?
|
| Gene Library | 1 | 2017 | 3 | 0.140 |
Why?
|
| Risk Assessment | 5 | 2024 | 1097 | 0.140 |
Why?
|
| Paraffin Embedding | 1 | 2017 | 5 | 0.140 |
Why?
|
| Calcium, Dietary | 3 | 2007 | 27 | 0.140 |
Why?
|
| Colorectal Neoplasms | 2 | 2014 | 613 | 0.140 |
Why?
|
| Suicidal Ideation | 3 | 2024 | 100 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 30 | 0.140 |
Why?
|
| Health Policy | 1 | 2018 | 122 | 0.140 |
Why?
|
| Pregnancy | 1 | 2022 | 1494 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2017 | 16 | 0.140 |
Why?
|
| Suicide, Attempted | 1 | 2018 | 96 | 0.140 |
Why?
|
| Tuberculosis | 1 | 2017 | 20 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 382 | 0.140 |
Why?
|
| Menarche | 2 | 2009 | 28 | 0.140 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2017 | 53 | 0.140 |
Why?
|
| Viral Load | 1 | 2017 | 135 | 0.140 |
Why?
|
| Population Surveillance | 1 | 2018 | 263 | 0.130 |
Why?
|
| Sex Distribution | 2 | 2017 | 190 | 0.130 |
Why?
|
| Age Distribution | 2 | 2017 | 246 | 0.130 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 1322 | 0.130 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 1900 | 0.120 |
Why?
|
| Cause of Death | 3 | 2021 | 181 | 0.120 |
Why?
|
| Age Factors | 4 | 2019 | 917 | 0.110 |
Why?
|
| ErbB Receptors | 1 | 2012 | 5 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 6 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2015 | 244 | 0.100 |
Why?
|
| Skinfold Thickness | 3 | 2006 | 18 | 0.100 |
Why?
|
| Minority Groups | 2 | 2023 | 101 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2012 | 159 | 0.090 |
Why?
|
| Prognosis | 3 | 2020 | 606 | 0.090 |
Why?
|
| Iron, Dietary | 2 | 2007 | 7 | 0.080 |
Why?
|
| Heart Failure | 1 | 2015 | 396 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2022 | 1115 | 0.080 |
Why?
|
| Dietary Fiber | 2 | 2007 | 59 | 0.080 |
Why?
|
| Depression | 2 | 2024 | 502 | 0.080 |
Why?
|
| Asian Americans | 2 | 2020 | 176 | 0.070 |
Why?
|
| Nutritional Requirements | 1 | 2007 | 6 | 0.070 |
Why?
|
| Body Fat Distribution | 1 | 2007 | 5 | 0.070 |
Why?
|
| Dietary Sucrose | 1 | 2007 | 12 | 0.070 |
Why?
|
| Nutrition Policy | 1 | 2007 | 18 | 0.070 |
Why?
|
| Skin | 1 | 2007 | 13 | 0.070 |
Why?
|
| Sunlight | 1 | 2007 | 13 | 0.070 |
Why?
|
| Vitamin D Deficiency | 1 | 2007 | 21 | 0.070 |
Why?
|
| Vitamin D | 1 | 2007 | 76 | 0.070 |
Why?
|
| European Continental Ancestry Group | 2 | 2020 | 529 | 0.070 |
Why?
|
| Asia | 1 | 2006 | 15 | 0.070 |
Why?
|
| Survival Rate | 2 | 2020 | 260 | 0.070 |
Why?
|
| Folic Acid | 1 | 2006 | 32 | 0.070 |
Why?
|
| Diet Surveys | 1 | 2006 | 57 | 0.070 |
Why?
|
| Smoking | 2 | 2022 | 483 | 0.070 |
Why?
|
| California | 2 | 2023 | 2284 | 0.060 |
Why?
|
| Milk | 1 | 2004 | 8 | 0.060 |
Why?
|
| Lactation | 1 | 2024 | 52 | 0.060 |
Why?
|
| Smoke | 1 | 2024 | 6 | 0.060 |
Why?
|
| Pyrrolidines | 1 | 2024 | 2 | 0.060 |
Why?
|
| Longitudinal Studies | 3 | 2018 | 710 | 0.060 |
Why?
|
| Pruritus | 1 | 2023 | 3 | 0.060 |
Why?
|
| Quinoxalines | 1 | 2024 | 12 | 0.060 |
Why?
|
| Bone Density | 1 | 2004 | 92 | 0.060 |
Why?
|
| Infant Formula | 1 | 2003 | 11 | 0.060 |
Why?
|
| Fatigue | 1 | 2023 | 34 | 0.060 |
Why?
|
| Schizophrenia | 1 | 2024 | 77 | 0.060 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2014 | 21 | 0.060 |
Why?
|
| Genotype | 1 | 2024 | 227 | 0.060 |
Why?
|
| Logistic Models | 2 | 2019 | 926 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 709 | 0.060 |
Why?
|
| Population Groups | 1 | 2023 | 8 | 0.050 |
Why?
|
| Body Weight | 1 | 2004 | 219 | 0.050 |
Why?
|
| Health Promotion | 1 | 2006 | 280 | 0.050 |
Why?
|
| Mutation | 2 | 2014 | 128 | 0.050 |
Why?
|
| Genetic Testing | 2 | 2014 | 70 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 140 | 0.050 |
Why?
|
| Child Health | 1 | 2023 | 35 | 0.050 |
Why?
|
| Exercise | 2 | 2004 | 489 | 0.050 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2022 | 7 | 0.050 |
Why?
|
| Regression Analysis | 3 | 2007 | 297 | 0.050 |
Why?
|
| Liver Transplantation | 1 | 2020 | 7 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 13 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 21 | 0.040 |
Why?
|
| Bilirubin | 1 | 2020 | 30 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2020 | 70 | 0.040 |
Why?
|
| Oceanic Ancestry Group | 1 | 2020 | 33 | 0.040 |
Why?
|
| Health Surveys | 1 | 2020 | 260 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2019 | 64 | 0.040 |
Why?
|
| Mammography | 2 | 2011 | 169 | 0.040 |
Why?
|
| Interferons | 1 | 2019 | 5 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 114 | 0.040 |
Why?
|
| Washington | 1 | 2020 | 374 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 42 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 671 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2023 | 1409 | 0.040 |
Why?
|
| Hospitalization | 1 | 2024 | 797 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 47 | 0.040 |
Why?
|
| Glycated Hemoglobin A | 1 | 2019 | 216 | 0.040 |
Why?
|
| Hispanic Americans | 1 | 2020 | 404 | 0.040 |
Why?
|
| Fibrosis | 1 | 2017 | 7 | 0.040 |
Why?
|
| Risk-Taking | 1 | 2018 | 109 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 4 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2017 | 42 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2018 | 155 | 0.030 |
Why?
|
| Ethnic Groups | 1 | 2020 | 485 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 630 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2019 | 341 | 0.030 |
Why?
|
| Biomarkers | 1 | 2017 | 301 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 1210 | 0.030 |
Why?
|
| Health Behavior | 1 | 2018 | 359 | 0.030 |
Why?
|
| Body Composition | 2 | 2007 | 82 | 0.030 |
Why?
|
| Pacific States | 1 | 2015 | 4 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 643 | 0.030 |
Why?
|
| Mass Screening | 1 | 2020 | 661 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 200 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 31 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2015 | 53 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 86 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 145 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2019 | 766 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 325 | 0.030 |
Why?
|
| Continental Population Groups | 1 | 2015 | 302 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 98 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 129 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 59 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 237 | 0.030 |
Why?
|
| Family Health | 1 | 2011 | 44 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 218 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 304 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 381 | 0.020 |
Why?
|
| Mothers | 1 | 2011 | 105 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2012 | 248 | 0.020 |
Why?
|
| Polynesia | 1 | 2009 | 1 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2007 | 23 | 0.020 |
Why?
|
| Dietary Proteins | 1 | 2007 | 20 | 0.020 |
Why?
|
| Dietary Carbohydrates | 1 | 2007 | 27 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 50 | 0.020 |
Why?
|
| Diet Records | 1 | 2007 | 36 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2007 | 6 | 0.020 |
Why?
|
| Energy Intake | 1 | 2007 | 101 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2007 | 91 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2007 | 116 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2004 | 61 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2004 | 85 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 37 | 0.010 |
Why?
|
| Animals | 1 | 2004 | 259 | 0.010 |
Why?
|
| Anthropometry | 1 | 2003 | 66 | 0.010 |
Why?
|
| Aging | 1 | 2003 | 161 | 0.010 |
Why?
|
| Breast Feeding | 1 | 2003 | 133 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2003 | 844 | 0.010 |
Why?
|
Concepts
(248)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(19)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->